Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Return on Sales (2023 - 2025)

CG Oncology (CGON) has disclosed Return on Sales for 3 consecutive years, with 17.77% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 5198.0% year-over-year to 17.77%, compared with a TTM value of 39.81% through Dec 2025, up 3749.0%, and an annual FY2025 reading of 39.81%, up 3749.0% over the prior year.
  • Return on Sales was 17.77% for Q4 2025 at CG Oncology, up from 26.24% in the prior quarter.
  • Across five years, Return on Sales topped out at 17.77% in Q4 2025 and bottomed at 16551.0% in Q4 2023.
  • Average Return on Sales over 3 years is 1780.77%, with a median of 170.36% recorded in 2024.
  • The sharpest move saw Return on Sales skyrocketed 1648125bps in 2024, then tumbled -63064bps in 2025.
  • Year by year, Return on Sales stood at 16551.0% in 2023, then skyrocketed by 100bps to 69.75% in 2024, then surged by 75bps to 17.77% in 2025.
  • Business Quant data shows Return on Sales for CGON at 17.77% in Q4 2025, 26.24% in Q3 2025, and 232.46% in Q2 2025.